I now have excellent content from Katzung's and Goodman & Gilman's textbooks. I have enough information to build a comprehensive, easy-to-understand table-form answer. Let me compile this now.
Blood & Haematinics - Pharmacology (Easy Table Guide)
Sources: Katzung's Basic and Clinical Pharmacology, 16e | Goodman & Gilman's Pharmacological Basis of Therapeutics
What Are Haematinics?
Haematinics are drugs that promote formation of blood cells - mainly red blood cells. The word comes from "haema" (blood) + "tonic." They correct anaemia by supplying what the bone marrow needs to make healthy red cells.
PART 1 - Iron Preparations (For Iron-Deficiency Anaemia)
| Drug | Form | Elemental Iron % | Dose | Key Notes |
|---|
| Ferrous sulfate | Oral | ~20% | 325 mg TDS | First choice - cheap, effective |
| Ferrous gluconate | Oral | ~12% | 300 mg TDS | Less GI upset than sulfate |
| Ferrous fumarate | Oral | ~33% | 200 mg BD | Highest % elemental iron orally |
| Carbonyl iron | Oral | ~100% | Lower dose | Slow release, safer in OD |
| Iron sucrose | IV | - | Per protocol | Used in CKD, malabsorption |
| Ferric carboxymaltose | IV | - | Single large dose | Less frequent infusions |
| Iron dextran | IV/IM | - | Per protocol | Risk of anaphylaxis |
Iron Absorption Tips (Easy Memory):
- Absorbed in duodenum + proximal jejunum as Fe²⁺ (ferrous form)
- Vitamin C increases absorption (converts Fe³⁺ → Fe²⁺)
- Tea, milk, antacids reduce absorption
- Give on empty stomach for best effect (take with food if GI upset occurs)
- Continue therapy 3-6 months after Hb normalizes to replenish stores
Side Effects of Oral Iron:
- Nausea, constipation, dark stools, epigastric pain
- GI side effects are dose-dependent
PART 2 - Vitamin B12 (Cobalamin) - For Megaloblastic Anaemia
| Aspect | Details |
|---|
| Drug | Cyanocobalamin, Hydroxocobalamin |
| Deficiency cause | Pernicious anaemia (lack of Intrinsic Factor), strict vegans, gastrectomy |
| Mechanism | Needed for DNA synthesis (thymidine synthesis) and myelin formation |
| Route | IM injection (if pernicious anaemia / malabsorption); oral if dietary deficiency |
| IM dose | 1000 mcg/day x 7 days → weekly x 4 weeks → monthly lifelong |
| Key finding | Megaloblastic (macrocytic) anaemia + neurological signs (subacute combined degeneration) |
| Trap! | Giving folate alone in B12 deficiency corrects anaemia but WORSENS neuro damage |
PART 3 - Folic Acid - For Megaloblastic Anaemia
| Aspect | Details |
|---|
| Drug | Folic acid (Vitamin B9) |
| Deficiency cause | Poor diet, pregnancy, alcohol, methotrexate/phenytoin use |
| Mechanism | Needed for purine and thymidine synthesis (DNA formation) |
| Route | Oral (well absorbed) |
| Dose | 1-5 mg/day orally |
| Prevention | 400 mcg/day in women planning pregnancy (prevents neural tube defects) |
| Key finding | Megaloblastic anaemia WITHOUT neurological signs |
PART 4 - Erythropoiesis-Stimulating Agents (ESAs)
These drugs mimic erythropoietin (EPO) - the hormone made by kidneys that tells bone marrow to make red cells.
| Drug | Frequency | Main Use | Key Warning |
|---|
| Epoetin alfa | 3x/week SC/IV | Anaemia in CKD, chemotherapy | ↑ CV risk if Hb >11 g/dL |
| Darbepoetin alfa | Weekly or 2-weekly | Same as epoetin | Longer half-life, less frequent dosing |
| Methoxy PEG-epoetin beta | Monthly | CKD anaemia | Longest duration |
Golden Rule: Use the lowest dose to avoid transfusion. Never target Hb >11 g/dL.
PART 5 - Colony Stimulating Factors (CSFs) - For WBC/Neutrophil Deficiency
| Drug | Type | Main Use | Key Point |
|---|
| Filgrastim (G-CSF) | Granulocyte CSF | Chemotherapy neutropenia, bone marrow transplant, chronic neutropenia | Given 24h after chemo; prophylactic if fever risk >20% |
| Pegfilgrastim | Long-acting G-CSF | Prevention of chemo-induced neutropenia | Given once per chemo cycle (longer acting) |
| Sargramostim (GM-CSF) | Granulocyte-Macrophage CSF | Bone marrow transplant, AML recovery | Stimulates both neutrophils and monocytes |
PART 6 - Thrombopoietin Receptor Agonists (Platelet Boosters)
For when platelet count is dangerously low (thrombocytopenia).
| Drug | Route | Main Use | Key Point |
|---|
| Romiplostim | SC injection | ITP (chronic) | Peptide TPO mimetic; weekly dosing |
| Eltrombopag | Oral | ITP, severe aplastic anaemia, HCV thrombocytopenia | Monitor liver function; can cause portal thrombosis |
| Avatrombopag | Oral | Chronic ITP, pre-procedure in liver disease | 5-day course before procedure |
| Lusutrombopag | Oral | Chronic liver disease thrombocytopenia pre-procedure | Similar to avatrombopag |
| Fostamatinib | Oral | Chronic ITP (failed other therapies) | SYK inhibitor; side effects: diarrhea, hypertension |
Shared Warnings: Do NOT target normal platelet counts - just enough to reduce bleeding risk (>50,000/µL). Risk of marrow fibrosis and rebound thrombocytopenia on stopping.
PART 7 - Anticoagulants (Blood Thinners) - Quick Summary
| Drug | Class | Mechanism | Use | Monitor |
|---|
| Heparin (UFH) | IV/SC | Activates antithrombin III → ↓ thrombin + Xa | DVT, PE, ACS (acute) | aPTT |
| LMWH (enoxaparin, dalteparin) | SC | Mainly anti-Xa | DVT prophylaxis/treatment | Anti-Xa level |
| Warfarin | Oral | Inhibits Vit K-dependent factors (II,VII,IX,X) | Chronic AF, mechanical valves, DVT | INR (target 2-3) |
| Dabigatran | Oral DOAC | Direct thrombin inhibitor | AF, VTE | No routine monitoring |
| Rivaroxaban / Apixaban | Oral DOAC | Direct factor Xa inhibitor | AF, VTE, PE | No routine monitoring |
PART 8 - Antiplatelet Drugs
| Drug | Mechanism | Use | Key Note |
|---|
| Aspirin | Irreversibly inhibits COX → ↓ TXA2 | ACS, stroke prevention, post-stent | Low dose (75-325 mg); lifelong after MI |
| Clopidogrel | ADP receptor (P2Y12) blocker | ACS, stents | Prodrug - requires CYP2C19; genetic variability |
| Ticagrelor | Reversible P2Y12 blocker | ACS | Faster onset than clopidogrel; causes dyspnea |
| Prasugrel | Irreversible P2Y12 blocker | ACS with PCI | More potent; avoid in stroke history |
| Abciximab / Eptifibatide | GPIIb/IIIa antagonist | High-risk PCI | IV only; blocks final platelet aggregation |
PART 9 - Thrombolytics (Clot Busters)
| Drug | Type | Use | Time Window |
|---|
| Streptokinase | Non-specific | STEMI, DVT, PE | Within 12h of MI |
| Alteplase (tPA) | Fibrin-specific | Ischemic stroke, STEMI, PE | Stroke: within 4.5h; STEMI: within 12h |
| Tenecteplase | Fibrin-specific, long-acting | STEMI | Single IV bolus (convenient) |
PART 10 - Haemostatics (Stop Bleeding)
| Drug | Mechanism | Use |
|---|
| Tranexamic acid | Inhibits fibrinolysis (anti-plasmin) | Trauma, surgical bleeding, menorrhagia |
| Aminocaproic acid | Same as above | Post-surgical bleeding |
| Vitamin K | Replenishes clotting factors | Warfarin reversal, Vit K deficiency bleeding |
| Protamine sulfate | Binds and neutralizes heparin | Heparin overdose antidote |
| FFP / Cryoprecipitate | Replaces all/specific clotting factors | DIC, massive transfusion |
| Desmopressin (DDAVP) | ↑ release of vWF from endothelium | Mild haemophilia A, vWD |
Quick Memory Summary
| Anaemia Type | Deficiency | Drug |
|---|
| Microcytic (small cells) | Iron | Ferrous sulfate / IV iron |
| Macrocytic (big cells) + neuro signs | Vitamin B12 | Cyanocobalamin IM |
| Macrocytic (big cells), no neuro | Folate | Folic acid oral |
| Normocytic in CKD | Low EPO | Epoetin alfa / Darbepoetin |
| Bone marrow failure | Multiple | G-CSF + transfusion |
Sources: Katzung's Basic and Clinical Pharmacology 16e (Chapter 33) | Goodman & Gilman's Pharmacological Basis of Therapeutics (Hematopoietic Agents chapter)